Kowa Submits NDA For Peretinoin To Reduce HCC Recurrence Risk
This article was originally published in PharmAsia News
Executive Summary
Nagoya-based Kowa has submitted a new drug application for a novel synthetic retinoid, peretinoin (NIK-333) to prevent the recurrence of liver cancer after surgical resection of primary tumors